Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 192

1.

An aqueous orally active vaccine targeted against a RAGE/AB complex as a novel therapeutic for Alzheimer's disease.

Webster SJ, Mruthinti S, Hill WD, Buccafusco JJ, Terry AV Jr.

Neuromolecular Med. 2012 Jun;14(2):119-30. doi: 10.1007/s12017-012-8176-z. Epub 2012 Mar 14.

PMID:
22415896
2.

The nicotine metabolite, cotinine, attenuates glutamate (NMDA) antagonist-related effects on the performance of the five choice serial reaction time task (5C-SRTT) in rats.

Terry AV Jr, Buccafusco JJ, Schade RF, Vandenhuerk L, Callahan PM, Beck WD, Hutchings EJ, Chapman JM, Li P, Bartlett MG.

Biochem Pharmacol. 2012 Apr 1;83(7):941-51. doi: 10.1016/j.bcp.2011.12.043. Epub 2012 Jan 8.

3.

Cholinergic modulation of working memory activity in primate prefrontal cortex.

Zhou X, Qi XL, Douglas K, Palaninathan K, Kang HS, Buccafusco JJ, Blake DT, Constantinidis C.

J Neurophysiol. 2011 Nov;106(5):2180-8. doi: 10.1152/jn.00148.2011. Epub 2011 Jul 27.

4.

The use-dependent, nicotinic antagonist BTMPS reduces the adverse consequences of morphine self-administration in rats in an abstinence model of drug seeking.

Hall BJ, Pearson LS, Terry AV Jr, Buccafusco JJ.

Neuropharmacology. 2011 Sep;61(4):798-806. doi: 10.1016/j.neuropharm.2011.05.026. Epub 2011 May 30.

5.

The acute effects of dimebolin, a potential Alzheimer's disease treatment, on working memory in rhesus monkeys.

Webster SJ, Wilson CA, Lee CH, Mohler EG, Terry AV Jr, Buccafusco JJ.

Br J Pharmacol. 2011 Oct;164(3):970-8. doi: 10.1111/j.1476-5381.2011.01432.x.

6.

Introduction.

Levin ED, Buccafusco JJ.

In: Levin ED, Buccafusco JJ, editors. Animal Models of Cognitive Impairment. Boca Raton (FL): CRC Press/Taylor & Francis; 2006. Chapter 1.

7.

Cognitive Pharmacology in Aging Macaques.

Buccafusco JJ.

In: Levin ED, Buccafusco JJ, editors. Animal Models of Cognitive Impairment. Boca Raton (FL): CRC Press/Taylor & Francis; 2006. Chapter 13.

8.

The Revival of Scopolamine Reversal for the Assessment of Cognition-Enhancing Drugs.

Buccafusco JJ.

In: Buccafusco JJ, editor. Methods of Behavior Analysis in Neuroscience. 2nd edition. Boca Raton (FL): CRC Press/Taylor & Francis; 2009. Chapter 17.

9.

Contextually Induced Drug Seeking During Protracted Abstinence in Rats.

Buccafusco JJ, Shuster L.

In: Buccafusco JJ, editor. Methods of Behavior Analysis in Neuroscience. 2nd edition. Boca Raton (FL): CRC Press/Taylor & Francis; 2009. Chapter 10.

10.

Repeated, intermittent exposures to diisopropylfluorophosphate in rats: protracted effects on cholinergic markers, nerve growth factor-related proteins, and cognitive function.

Terry AV Jr, Buccafusco JJ, Gearhart DA, Beck WD, Middlemore-Risher ML, Truan JN, Schwarz GM, Xu M, Bartlett MG, Kutiyanawala A, Pillai A.

Neuroscience. 2011 Mar 10;176:237-53. doi: 10.1016/j.neuroscience.2010.12.031. Epub 2010 Dec 24.

11.

The prototypical ranitidine analog JWS-USC-75-IX improves information processing and cognitive function in animal models.

Terry AV Jr, Buccafusco JJ, Herman EJ, Callahan PM, Beck WD, Warner S, Vandenhuerk L, Bouchard K, Schwarz GM, Gao J, Chapman JM.

J Pharmacol Exp Ther. 2011 Mar;336(3):751-66. doi: 10.1124/jpet.110.175422. Epub 2010 Nov 24.

12.

Ganglioside metabolism in a transgenic mouse model of Alzheimer's disease: expression of Chol-1α antigens in the brain.

Ariga T, Yanagisawa M, Wakade C, Ando S, Buccafusco JJ, McDonald MP, Yu RK.

ASN Neuro. 2010 Oct 4;2(4):e00044. doi: 10.1042/AN20100021.

13.

The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures.

Millan MJ, Buccafusco JJ, Loiseau F, Watson DJ, Decamp E, Fone KC, Thomasson-Perret N, Hill M, Mocaer E, Schneider JS.

Int J Neuropsychopharmacol. 2010 Sep;13(8):1035-51. doi: 10.1017/S1461145710000775. Epub 2010 Jul 22.

PMID:
20663270
14.

RAGE and Abeta immunoglobulins: relation to Alzheimer's disease-related cognitive function.

Mitchell MB, Buccafusco JJ, Schade RF, Webster SJ, Mruthinti S, Harrell DU, Gulati NK, Miller LS.

J Int Neuropsychol Soc. 2010 Jul;16(4):672-8. doi: 10.1017/S1355617710000469. Epub 2010 May 5.

PMID:
20441687
15.

Therapeutics for cognitive aging.

Shineman DW, Salthouse TA, Launer LJ, Hof PR, Bartzokis G, Kleiman R, Luine V, Buccafusco JJ, Small GW, Aisen PS, Lowe DA, Fillit HM.

Ann N Y Acad Sci. 2010 Apr;1191 Suppl 1:E1-15. doi: 10.1111/j.1749-6632.2010.05532.x.

16.

Repeated exposures to low-level chlorpyrifos results in impairments in sustained attention and increased impulsivity in rats.

Middlemore-Risher ML, Buccafusco JJ, Terry AV Jr.

Neurotoxicol Teratol. 2010 Jul-Aug;32(4):415-24. doi: 10.1016/j.ntt.2010.03.008. Epub 2010 Mar 27.

17.

Effect of the use-dependent, nicotinic receptor antagonist BTMPS in the forced swim test and elevated plus maze after cocaine discontinuation in rats.

Hall BJ, Pearson LS, Buccafusco JJ.

Neurosci Lett. 2010 Apr 26;474(2):84-7. doi: 10.1016/j.neulet.2010.03.011. Epub 2010 Mar 10.

PMID:
20226229
18.

Treatments for neuropathic pain differentially affect delayed matching accuracy by macaques: effects of amitriptyline and gabapentin.

Buccafusco JJ, Terry AV Jr, Vazdarjanova A, Snutch TP, Arneric SP.

Pain. 2010 Mar;148(3):446-53. doi: 10.1016/j.pain.2009.12.003. Epub 2010 Jan 25.

PMID:
20092945
19.

Effect of administration of the nicotinic acetylcholine receptor antagonist BTMPS, during nicotine self-administration, on lever responding induced by context long after withdrawal.

Hall BJ, Pearson LS, Buccafusco JJ.

Neuropharmacology. 2010 Feb;58(2):429-35. doi: 10.1016/j.neuropharm.2009.09.009. Epub 2009 Sep 20.

PMID:
19772864
20.

Emerging cognitive enhancing drugs.

Buccafusco JJ.

Expert Opin Emerg Drugs. 2009 Dec;14(4):577-89. doi: 10.1517/14728210903257796. Review.

PMID:
19772371
21.

A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists.

Buccafusco JJ, Terry AV Jr.

Biochem Pharmacol. 2009 Oct 1;78(7):852-62. doi: 10.1016/j.bcp.2009.06.102. Epub 2009 Jul 3.

22.

Anomaly in aortic arch alters pathological outcome of transient global ischemia in Rhesus macaques.

Hara K, Yasuhara T, Maki M, Matsukawa N, Yu G, Xu L, Tambrallo L, Rodriguez NA, Stern DM, Yamashima T, Buccafusco JJ, Kawase T, Hess DC, Borlongan CV.

Brain Res. 2009 Aug 25;1286:185-91. doi: 10.1016/j.brainres.2009.06.015. Epub 2009 Jun 12.

23.

Anti-RAGE and Abeta immunoglobulin levels are related to dementia level and cognitive performance.

Wilson JS, Mruthinti S, Buccafusco JJ, Schade RF, Mitchell MB, Harrell DU, Gulati NK, Miller LS.

J Gerontol A Biol Sci Med Sci. 2009 Feb;64(2):264-71. doi: 10.1093/gerona/gln002. Epub 2009 Feb 5.

24.

Multifunctional receptor-directed drugs for disorders of the central nervous system.

Buccafusco JJ.

Neurotherapeutics. 2009 Jan;6(1):4-13. doi: 10.1016/j.nurt.2008.10.031. Review.

25.

Estimation of working memory in macaques for studying drugs for the treatment of cognitive disorders.

Buccafusco JJ.

J Alzheimers Dis. 2008 Dec;15(4):709-20. Review.

PMID:
19096166
26.

Desensitization of nicotinic acetylcholine receptors as a strategy for drug development.

Buccafusco JJ, Beach JW, Terry AV Jr.

J Pharmacol Exp Ther. 2009 Feb;328(2):364-70. doi: 10.1124/jpet.108.145292. Epub 2008 Nov 20. Review.

27.

Protracted cognitive effects produced by clonidine in Macaca nemestrina performing a delayed matching task.

Buccafusco JJ, Webster SJ, Terry AV Jr, Kille N, Blessing D.

Psychopharmacology (Berl). 2009 Jan;202(1-3):477-85. doi: 10.1007/s00213-008-1318-1. Epub 2008 Sep 11.

PMID:
18784917
28.

Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets.

Terry AV Jr, Buccafusco JJ, Wilson C.

Behav Brain Res. 2008 Dec 16;195(1):30-8. doi: 10.1016/j.bbr.2007.12.006. Epub 2008 Feb 1. Review.

PMID:
18241938
29.
30.

Profile of nicotinic acetylcholine receptor agonists ABT-594 and A-582941, with differential subtype selectivity, on delayed matching accuracy by young monkeys.

Buccafusco JJ, Terry AV Jr, Decker MW, Gopalakrishnan M.

Biochem Pharmacol. 2007 Oct 15;74(8):1202-11. Epub 2007 Jul 14.

PMID:
17706609
31.

The effects of JWB1-84-1 on memory-related task performance by amyloid Abeta transgenic mice and by young and aged monkeys.

Sood A, Warren Beach J, Webster SJ, Terry AV, Buccafusco JJ.

Neuropharmacology. 2007 Oct;53(5):588-600. Epub 2007 Jul 14.

PMID:
17698153
32.

Hippocampal CA1 cell loss in a non-human primate model of transient global ischemia: a pilot study.

Hara K, Yasuhara T, Matsukawa N, Maki M, Masuda T, Yu G, Xu L, Tambrallo L, Rodriguez NA, Stern DM, Kawase T, Yamashima T, Buccafusco JJ, Hess DC, Borlongan CV.

Brain Res Bull. 2007 Sep 14;74(1-3):164-71.

PMID:
17683803
33.

The scopolamine-reversal paradigm in rats and monkeys: the importance of computer-assisted operant-conditioning memory tasks for screening drug candidates.

Buccafusco JJ, Terry AV Jr, Webster SJ, Martin D, Hohnadel EJ, Bouchard KA, Warner SE.

Psychopharmacology (Berl). 2008 Aug;199(3):481-94. Epub 2007 Jul 27.

PMID:
17657478
34.

Chronic, intermittent exposure to chlorpyrifos in rats: protracted effects on axonal transport, neurotrophin receptors, cholinergic markers, and information processing.

Terry AV Jr, Gearhart DA, Beck WD Jr, Truan JN, Middlemore ML, Williamson LN, Bartlett MG, Prendergast MA, Sickles DW, Buccafusco JJ.

J Pharmacol Exp Ther. 2007 Sep;322(3):1117-28. Epub 2007 Jun 4.

PMID:
17548533
35.

MHP-133, a drug with multiple CNS targets: potential for neuroprotection and enhanced cognition.

Buccafusco JJ, Powers JC, Hernandez MA, Prendergast MA, Terry AV, Jonnala RR.

Neurochem Res. 2007 Jul;32(7):1224-37. Epub 2007 Apr 3. Erratum in: Neurochem Res. 2007 Oct;32(10):1719.

PMID:
17404838
36.

Microtubule-associated targets in chlorpyrifos oxon hippocampal neurotoxicity.

Prendergast MA, Self RL, Smith KJ, Ghayoumi L, Mullins MM, Butler TR, Buccafusco JJ, Gearhart DA, Terry AV Jr.

Neuroscience. 2007 Apr 25;146(1):330-9. Epub 2007 Feb 22.

37.

Disconnection between activation and desensitization of autonomic nicotinic receptors by nicotine and cotinine.

Buccafusco JJ, Shuster LC, Terry AV Jr.

Neurosci Lett. 2007 Feb 8;413(1):68-71. Epub 2006 Dec 8.

PMID:
17157984
38.

Chlorpyrifos, chlorpyrifos-oxon, and diisopropylfluorophosphate inhibit kinesin-dependent microtubule motility.

Gearhart DA, Sickles DW, Buccafusco JJ, Prendergast MA, Terry AV Jr.

Toxicol Appl Pharmacol. 2007 Jan 1;218(1):20-9. Epub 2006 Oct 17.

PMID:
17123561
39.

Guidelines on nicotine dose selection for in vivo research.

Matta SG, Balfour DJ, Benowitz NL, Boyd RT, Buccafusco JJ, Caggiula AR, Craig CR, Collins AC, Damaj MI, Donny EC, Gardiner PS, Grady SR, Heberlein U, Leonard SS, Levin ED, Lukas RJ, Markou A, Marks MJ, McCallum SE, Parameswaran N, Perkins KA, Picciotto MR, Quik M, Rose JE, Rothenfluh A, Schafer WR, Stolerman IP, Tyndale RF, Wehner JM, Zirger JM.

Psychopharmacology (Berl). 2007 Feb;190(3):269-319. Epub 2006 Aug 9. Review.

PMID:
16896961
40.

The induction of surface beta-amyloid binding proteins and enhanced cytotoxicity in cultured PC-12 and IMR-32 cells by advanced glycation end products.

Mruthinti S, Sood A, Humphrey CL, Swamy-Mruthinti S, Buccafusco JJ.

Neuroscience. 2006 Oct 13;142(2):463-73. Epub 2006 Aug 4.

PMID:
16890367
41.

Autoimmunity in Alzheimer's disease as evidenced by plasma immunoreactivity against RAGE and Abeta42: complication of diabetes.

Mruthinti S, Schade RF, Harrell DU, Gulati NK, Swamy-Mruthinti S, Lee GP, Buccafusco JJ.

Curr Alzheimer Res. 2006 Jul;3(3):229-35.

PMID:
16842100
42.

Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder.

Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD, Kay G, Laties A, Nathanson NM, Pasricha PJ, Wein AJ.

Br J Pharmacol. 2006 Jul;148(5):565-78. Epub 2006 Jun 5. Review.

43.

Cotinine, a neuroactive metabolite of nicotine: potential for treating disorders of impaired cognition.

Terry AV Jr, Hernandez CM, Hohnadel EJ, Bouchard KP, Buccafusco JJ.

CNS Drug Rev. 2005 Autumn;11(3):229-52. Review.

44.

The electromyographic signal as a presymptomatic indicator of organophosphates in the body.

De Luca CJ, Buccafusco JJ, Roy SH, De Luca G, Nawab SH.

Muscle Nerve. 2006 Mar;33(3):369-76.

PMID:
16307441
45.

Effect of amyloid peptides on the increase in TrkA receptor expression induced by nicotine in vitro and in vivo.

Li XD, Arias E, Jonnala RR, Mruthinti S, Buccafusco JJ.

J Mol Neurosci. 2005;27(3):325-36.

PMID:
16280603
46.

Functional central nicotinic acetylcholine receptor antagonism by systemic administration of Tinuvin 770 (BTMPS).

Graham JH, Papke RL, Buccafusco JJ.

Curr Alzheimer Res. 2005 Apr;2(2):141-7.

PMID:
15974911
47.

Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic discordance.

Buccafusco JJ, Letchworth SR, Bencherif M, Lippiello PM.

Trends Pharmacol Sci. 2005 Jul;26(7):352-60. Review.

PMID:
15946748
48.

CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases.

Youdim MB, Buccafusco JJ.

J Neural Transm (Vienna). 2005 Apr;112(4):519-37. Epub 2005 Jan 24. Review.

PMID:
15666041
49.

Novel analogs of choline as potential neuroprotective agents.

Buccafusco JJ, Beach JW, Terry AV Jr, Doad GS, Sood A, Arias E, Misawa H, Masai M, Fujii T, Kawashima K.

J Alzheimers Dis. 2004 Dec;6(6 Suppl):S85-92.

PMID:
15665419
50.

Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders.

Youdim MB, Buccafusco JJ.

Trends Pharmacol Sci. 2005 Jan;26(1):27-35. Review.

PMID:
15629202

Supplemental Content

Loading ...
Support Center